Search - tctmd.com

Displaying 81 - 100 of 343

Sort: Relevancy | Date

Presentation TCT 2021

The Journey in Clinical Context (Case Presentation)

Presenter: Itsik Ben-Dor

November 05, 2021

Presentation TCT 2021

Innovation in the TAVR Space: Remaining Challenges and Opportunities

Presenter: Eberhard Grube

November 05, 2021

Presentation TCT 2021

Left Atrial Appendage Interventions – Closing the Key Evidence Gaps to Move the Field Forward, From FDA Perspective

Presenter: Kan Fang

November 05, 2021

Presentation TCT 2021

Tricuspid Valve Interventions - Adding Quality of Life to Years, from Industry Perspective

Presenter: Suzanne Arnold

November 05, 2021

Presentation TCT 2021

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

Presenter: Dhanunjaya Lakkireddy

November 05, 2021

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

Presentation TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Presenter: David Cohen

November 05, 2021

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

Todd Neale

November 05, 2021

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Presenter: Ori Ben-Yehuda

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Presenter: Joanna Chikwe

November 05, 2021

Presentation TCT 2021

Pro: TEER Is the Optimal Therapy TODAY!

Presenter: Saibal Kar

November 05, 2021

Presentation TCT 2021

TCT 105: Impact of pulmonary hypertension differentiation on the outcome of patients undergoing MitraClip® therapy

Presenter: Tobias Schmidt

November 05, 2021

Presentation TCT 2021

New Insights From COAPT

Presenter: Gregg Stone

November 05, 2021

Presentation TCT 2021

Emerging Data From the TVT and STS Mitral Registries

Presenter: Paul Sorajja

November 05, 2021

Presentation TCT 2021

What’s New in the 2020 Valvular Heart Disease Guidelines for Primary and Secondary MR?

Presenter: Robert Bonow

November 05, 2021

Presentation TCT 2021

TCT 103: Safety and Effectiveness of Transcatheter Edge-to-Edge Repair With MitraClip™ in Atrial Functional MR: An Analysis of the Global EXPAND Study

Presenter: Nishtha Sodhi

November 05, 2021

Presentation TCT 2021

TCT 102: Assessing the Risk of Neo-Left Ventricular Outflow Tract Obstruction in Transcatheter Mitral Valve Replacement: Are We Treating All the Patients That Can be Treated?

Presenter: Keshav Kohli

November 05, 2021

Presentation TCT 2021

TCT 51: Complete Cerebral Protection via Left Radial Approach during Transcatheter Aortic Valve Replacement – Results from the PROTEMBO C Trial

Presenter: Tobias Schmidt

November 05, 2021

Advertisement

The Journey in Clinical Context (Case Presentation)

Innovation in the TAVR Space: Remaining Challenges and Opportunities

Left Atrial Appendage Interventions – Closing the Key Evidence Gaps to Move the Field Forward, From FDA Perspective

Tricuspid Valve Interventions - Adding Quality of Life to Years, from Industry Perspective

AMULET IDE: One-Year Device Closure From a Randomized Trial of Amulet Versus Watchman for Left Atrial Appendage Occlusion

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Pro: TEER Is the Optimal Therapy TODAY!

TCT 105: Impact of pulmonary hypertension differentiation on the outcome of patients undergoing MitraClip® therapy

New Insights From COAPT

Emerging Data From the TVT and STS Mitral Registries

What’s New in the 2020 Valvular Heart Disease Guidelines for Primary and Secondary MR?

TCT 103: Safety and Effectiveness of Transcatheter Edge-to-Edge Repair With MitraClip™ in Atrial Functional MR: An Analysis of the Global EXPAND Study

TCT 102: Assessing the Risk of Neo-Left Ventricular Outflow Tract Obstruction in Transcatheter Mitral Valve Replacement: Are We Treating All the Patients That Can be Treated?

TCT 51: Complete Cerebral Protection via Left Radial Approach during Transcatheter Aortic Valve Replacement – Results from the PROTEMBO C Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content